Will expand the reasoning for a 2 year timeframe. (this is ignoring speculation gains on results leading to the end of the trial)
Quoting the BYS report "We assume P2b launch in Q4 2017, completion Q1 2019. 3-5 months to ink a deal ~ June 2019" (Page 17 on valuation).
What has changed from then is a quarter extension and the proposition of recruiting far more than 30 patients for the larger outcome of segmented licenses per disease. The large unknown is how many patients extra, and how fast they can recruit - giving a big flux on that timeframe.
So adding a quarter longer than anticipated in the report and another two quarters for the numbers - thats why I say 2 years, and some for an deal to ink. It wasn't so much to rattle stormer but help get the mentality that it will probably take longer than expected.
- Forums
- ASX - By Stock
- DXB
- Ann: Ethics Committee Approval for Pharmacokinetic Trial
Ann: Ethics Committee Approval for Pharmacokinetic Trial, page-49
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
45.0¢ |
Change
0.015(3.45%) |
Mkt cap ! $247.7M |
Open | High | Low | Value | Volume |
44.0¢ | 46.5¢ | 42.5¢ | $1.090M | 2.454M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 63703 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.0¢ | 35469 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 63703 | 0.450 |
4 | 86106 | 0.445 |
2 | 34093 | 0.440 |
3 | 86821 | 0.435 |
6 | 147222 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.460 | 35469 | 2 |
0.465 | 61821 | 2 |
0.470 | 115603 | 5 |
0.475 | 344321 | 6 |
0.480 | 71700 | 2 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online